MULTI-UNIT PARTICULATE SYSTEM OF COMBINATION OF GARLIC, CELERY, CHIEF PUMPKIN, CUCUMBER, AND BAY LEAF EXTRACTS AS AN ANTIHYPERTENSIVE ADJUVANT

IDS00202606983APending Publication Date: 2026-07-17DIVISI HILIRISASI DAN KEKAYAAN INTELEKTUAL UNIVERSITAS BHAKTI KENCANA

Patent Information

Authority / Receiving Office
ID · ID
Patent Type
Utility models
Current Assignee / Owner
DIVISI HILIRISASI DAN KEKAYAAN INTELEKTUAL UNIVERSITAS BHAKTI KENCANA
Filing Date
2026-06-29
Publication Date
2026-07-17
Patent Text Reader

Abstract

This invention relates to a multi-unit particulate drug delivery system containing a combination of garlic (Allium sativum), celery (Apium graveolens), chayote (Sechium edule), cucumber (Cucumis sativus), and bay leaf (Syzigium polyanthum) extracts as an antihypertensive adjuvant. The system consists of discrete spherical particles with a size of 500–1200 µm that are homogeneously distributed in one oral dosage unit. The particles are prepared by wet granulation or extrusion-spheronization methods using suitable pharmaceutical excipients, with a final moisture content of less than 5% and a uniform particle size distribution. The combination of extracts is prepared in a certain ratio and standardized against active marker compounds, including allicin, apigenin, total flavonoids, and total phenolics.This system is designed to improve the stability of the active ingredient, reduce variation between dosage units, and produce a more controlled release profile compared to conventional powder blend formulations. Particles can be coated with hydrophilic polymers to produce a gradual release over 4–8 hours. Network pharmacology-based analysis shows that the extract combination acts simultaneously on several molecular targets involved in blood pressure regulation, including ACE, AGTR1, and NOS3, through modulation of the renin-angiotensin system and the nitric oxide pathway. Pharmacological tests in animal models of hypertension showed a significant reduction in systolic and diastolic blood pressure compared to controls. Accelerated stability tests at 40°C and 75% relative humidity for three months showed changes in marker compound levels of less than 5%.This invention can be applied in industry and packaged in capsule or sachet form as additional therapy in the management of hypertension.
Need to check novelty before this filing date? Find Prior Art